Carvana Co vs ImmunityBio Inc. Common Stock — how do they compare? Carvana Co trades at $63.6 (market cap $69.07B), while ImmunityBio Inc. Common Stock trades at $9.99 (market cap $10.33B). The key difference: Carvana Co is far larger — about 6.7× ImmunityBio Inc. Common Stock's market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and ImmunityBio Inc. Common Stock for 0 Days on average.
| CVNA | IBRX | |
|---|---|---|
Market Cap | $69.07B | $10.33B |
Volume | 6,556,641 | 11,745,198 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $11.55 |
52-Week Low | $56.27 | $1.98 |
Typical Hold Time | 28 Days | 0 Days |
Enterprise Value | $71.55B | $10.79B |
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $63.21, down 1.02% on the day, with a bearish technical signal from moving averages. The company reported strong fundamentals, including Q2 2026 EPS of $0.42 beating estimates, revenue growth to $20.32B in 2025, and a net income margin of 6.26%. Recent news highlights robust sales performance, with Jefferies noting September unit sales 40% above estimates. Cash flow trends show positive operational growth, though high debt levels and an elevated EV/EBITDA of 503.9 pose concerns.
The outlook for CVNA is mixed; strong revenue growth and operational improvements support upside potential, with a consensus price target of $84.07 implying significant appreciation. However, risks include high valuation multiples, substantial long-term debt of $5.26B, and bearish technical indicators. Investors should weigh robust earnings beats against volatility and leverage concerns.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →